Skip to main content

Year: 2022

Theralase® Grants Stock Options

TORONTO, Nov. 21, 2022 (GLOBE NEWSWIRE) — Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to destroy various cancers, bacteria and viruses, safely and effectively, announces the grant of stock options. The Company has granted an aggregate of 7,860,000 stock options to directors, officers, employees & advisory board members pursuant to the Company’s stock option plan. The options granted, are exercisable at a price of CDN$0.25 per share and vest over a three-year period and expire five years from the date of the grant. The stock option plan was last approved by the shareholders of the Company at the Annual General...

Continue reading

TELA Bio to Participate in Piper Sandler 34th Annual Healthcare Conference

MALVERN, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that the Company will participate in the Piper Sandler 34th Annual Healthcare Conference on November 30th, 2022. TELA’s management is scheduled to present at the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30th, 2022, at 11:30 am ET. Interested parties can access the live and archived webcast at ir.telabio.com. About TELA Bio, Inc. TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes...

Continue reading

Anfield Expands its Artillery Peak Uranium Project and Commissions BRS Inc. to Complete a Uranium Resource Report

VANCOUVER, British Columbia, Nov. 21, 2022 (GLOBE NEWSWIRE) — Anfield Energy Inc. (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT: 0AD) (“Anfield” or “the Company”) is pleased to announce that it has expanded its claim holdings in the uranium-rich Artillery Peak project area, located in Mohave County, Arizona (the “Claims”). The additional 54 Claims are contiguous to to Anfield’s current project in the Date Creek Basin and increase Anfield’s claim holdings in the area to 119. In addition, the Company has commissioned BRS Inc., an engineering firm, to complete an NI 43-101 uranium resource report for its combined Date Creek Basin/Artillery Peak projects. As stated in Anfield’s November 15 news release, historical records indicate a potential uranium resource in the Artillery Peak/Date Creek Basin area of approximately 2.8 million pounds of...

Continue reading

Boralex commissions the first repowered wind farm in the French department of Somme

PARIS, Nov. 21, 2022 (GLOBE NEWSWIRE) — Boralex Inc. (“Boralex” or the “Company”) (TSX: BLX) is pleased to announce the commissioning of the Bougainville Repowering wind farm in the French department of Somme (Hauts-de-France region). The repowering of the wind farm, which was first commissioned in 2005 and has been operated by Boralex since 2018, has increased production by more than 50% through the installation of 6 next-generation wind turbines, for an upgraded installed capacity of 18 MW.Project statistics:Commissioning date: November 15, 2022 Wind turbines: 6 Vestas V126 Total capacity before repowering: 12 MW Total capacity after repowering: 18 MW Equivalence in household energy needs met after repowering: 16,000+ householdsInitially commissioned in 2005, the Bougainville wind farm is the industry’s first wind energy...

Continue reading

Builders FirstSource Announces CEO Transition

Dave Rush Appointed Interim Chief Executive OfficerDave Flitman to Step Down to Pursue New OpportunityReaffirming Full Year 2022 Guidance DALLAS, Nov. 21, 2022 (GLOBE NEWSWIRE) — Builders FirstSource, Inc. (NYSE: BLDR) (“Builders FirstSource” or the “Company”) today announced that its Chief Executive Officer, Dave Flitman, has stepped down as President, CEO and member of the Board of Directors (the “Board”) to accept another opportunity outside of the industry. The Board has appointed Dave Rush, Executive Vice President, to serve as interim Chief Executive Officer, effective immediately, until a permanent successor is named. The Board has also formed a special committee, led by Chairman Paul Levy, to oversee the search for a new CEO. Rush, 60, has spent 23 years with Builders FirstSource. In his current role as Executive...

Continue reading

Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy

Treatment with UNI-494 improved contrast vision in animal models of geographic atrophy (GA) GA is an advanced form of Age-related Macular Degeneration (AMD) and there are currently no FDA-approved drugs to slow the progression of AMD LOS ALTOS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs, today announced key findings of UNI-494 efficacy from a preclinical study in animal models of Geographic Atrophy (GA). UNI-494 is a mitochondrial potassium channel (mitochondrial KATP) activator in development for treating diseases affected by mitochondrial dysfunction, such as kidney, liver, and ocular diseases. Mitochondrial dysfunction is implicated in Age-related Macular Degeneration (AMD) progression....

Continue reading

ASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference

SAN MATEO, Calif. and SINGAPORE, Nov. 21, 2022 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to participate in a fireside chat at the Piper Sandler Healthcare Conference on Thursday, December 1, 2022, at 8:30am ET. The conference will be held from November 29 to December 1, 2022, in-person at the Lotte New York Palace Hotel, New York, NY. A replay of the fireside chat will be made available on the Investor Relations section of ASLAN’s website and can be accessed directly at this link. Management will be available for one-on-one meetings with investors throughout the conference. Please contact your representative at Piper Sandler to schedule...

Continue reading

Helium Evolution Provides Update on First Farmout Well Drilled by North American Helium

CALGARY, Alberta, Nov. 21, 2022 (GLOBE NEWSWIRE) — Helium Evolution Incorporated (TSXV:HEVI) (“HEVI” or the “Company“), a Canadian-based helium exploration and production company focused on finding, developing and commercializing assets in southern Saskatchewan, today provides an update on the first of two wells that will be drilled by year end 2022 (the “First Test Well”), NAH Grasslands 13-30-2-8W3, on farmout lands within Block 1 at Mankota in Saskatchewan. The First Test Well was drilled and fully funded by HEVI’s farmout partner, North American Helium (“NAH”), pursuant to a previously announced farmout arrangement (see press releases dated October 21, 2022, and June 28, 2022). After reaching total depth over the weekend, NAH has informed HEVI that the open hole portion of the First Test Well will be...

Continue reading

NXT Reminds Shareholders of Previously Announced Rights Offering and Potential Accelerated Cut Off Times

CALGARY, Alberta, Nov. 21, 2022 (GLOBE NEWSWIRE) — NXT Energy Solutions Inc. (“NXT” or the “Company”) (TSX: SFD; OTCQB: NSFDF) would like to remind its shareholders of the upcoming deadlines and essential details of its previously announced rights offering (the “Rights Offering”) made to the holders of common shares of the Company (“Common Shares”) of record at the close of business on November 7, 2022 (the “Record Date”). The rights (“Rights”) will expire at 4:30 p.m. (Calgary time) on November 30, 2022 (the “Expiry Time”), after which time unexercised Rights will be void and of no value. Accelerated Deadlines It is important to note that intermediaries may have different cut off times prior to the Expiry Time, which could be as early as November 22, 2022. As such, the Company recommends...

Continue reading

Horizon Media Selects PubMatic as Exclusive Partner to Provide Advertisers with Data-Driven Advertising at Scale

Supply Path Optimization Agreement Brings Buyers Efficiency Across CTV and Omnichannel Formats NEW YORK and REDWOOD CITY, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) — Horizon Media, the largest media agency in the U.S., today announced a supply path optimization (SPO) partnership with PubMatic (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain of the future. Buying premium media inventory has become increasingly complex across formats and devices, with new challenges in targeting fragmented audiences. Partnering with PubMatic will add value to Horizon Media clients’ direct, transparent, and simplified access to high-value audiences and premium inventory, including CTV, at unprecedented scale. “Horizon’s relationship with PubMatic gives our clients access to audiences at scale across channels,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.